(Photo credit: Wikipedia) This morning, at the annual Biotechnology Industry Organization (BIO) Investor Forum in San Francisco, I'm hosting a panel discussion on the increasingly popular hypothesis that cancer stem cells (CSCs) play a vital role in tumor recalcitrance. The panel includes senior executives from three CSC-focused companies -- OncoMed, Stemline Therapeutics, [...]
